Ding-Feng Su
Overview
Explore the profile of Ding-Feng Su including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
181
Citations
4532
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tong L, Wang Z, Zhang J, Wang Y, Liu W, Yin H, et al.
Cell Death Discov
. 2021 Nov;
7(1):344.
PMID: 34759279
Macrophages play a vital role in the development of atherosclerosis. Previously, we have found that swiprosin-1 was abundantly expressed in macrophages. Here, we investigated the role of swiprosin-1 expressed in...
2.
Xu Z, Zhang J, Kong N, Zhang G, Ke P, Han T, et al.
Front Pharmacol
. 2021 May;
12:676589.
PMID: 33995108
The α7 nicotinic acetylcholine receptor (α7nAChR) belongs to the superfamily of cys loop cationic ligand-gated channels, which consists of homogeneous α7 subunits. Although our lab found that activation of α7nAChR...
3.
Xu Z, Zhang W, Su D, Zhang G, Miao C
Ann Transl Med
. 2021 Apr;
9(6):509.
PMID: 33850906
The α7 nicotinic acetylcholine receptor (α7nAChR) has been studied for many years since its discovery. Although many functions and characteristics of brain α7nAChR are widely understood, much remains to be...
4.
Xu T, Wang P, Tian J, Qing S, Wang S, Huang Y, et al.
Acta Pharmacol Sin
. 2021 Mar;
42(6):885-897.
PMID: 33782540
Hypertension is a serious public health problem worldwide. MT-1207, chemically named 3-(4-(4-(1H-benzotriazole-1-yl)butyl)piperazine-1-yl) benzisothiazole hydrochloride, is a new chemical entity that has entered into clinical trial as antihypertensive agent in China....
5.
Activation of the Cholinergic Anti-Inflammatory Pathway as a Novel Therapeutic Strategy for COVID-19
Qin Z, Xiang K, Su D, Sun Y, Liu X
Front Immunol
. 2021 Feb;
11:595342.
PMID: 33633726
The outbreak of coronavirus disease 2019 (COVID-19) underlined the urgent need for alleviating cytokine storm. We propose here that activating the cholinergic anti-inflammatory pathway (CAP) is a potential therapeutic strategy....
6.
Wang Z, Wang S, Xu T, Hong C, Cheng M, Zhu P, et al.
CNS Neurosci Ther
. 2020 Feb;
26(7):682-697.
PMID: 32087606
Background And Purpose: Cerebral organoids (COs) have been used for studying brain development, neural disorders, and species-specific drug pharmacology and toxicology, but the potential of COs transplantation therapy for brain...
7.
Song X, Cheng Y, Su D, Liu A
J Pharmacol Sci
. 2019 Jun;
140(1):79-85.
PMID: 31178326
Bone marrow failure is a disease syndrome with the disability to produce mature blood cells. Pancytopenia is the most common manifestation of bone marrow failure. Sirt1 is important for the...
8.
Wan J, Wang P, Zhang Y, Qin Z, Sun Y, Hu B, et al.
J Cell Physiol
. 2019 Apr;
234(11):20533-20545.
PMID: 31026065
The only Food and Drug Administration-approved treatment for acute ischemic stroke is tissue plasminogen activator, and the discovery of novel therapeutic targets is critical. Here, we found orosomucoid (ORM), an...
9.
Peng C, Dong X, Liu J, Tao Y, Xu C, Wang L, et al.
Clin Sci (Lond)
. 2018 Jul;
132(16):1797-1810.
PMID: 30006482
There is a pressing need for new approaches to prevent stroke. Endothelial progenitor cells (EPCs) promote vascular repair and revascularization in the ischemic brain. The present study sought to evaluate...
10.
Zhang L, Zhang Y, Cheng Y, Zhang J, Liu H, Wang W, et al.
CNS Neurosci Ther
. 2018 Jul;
24(9):828-836.
PMID: 29962085
Aims: It is unclear whether the impaired BRS plays a key role in the incidence of cardiovascular diseases. The molecular mechanism of impaired BRS remains to be fully elucidated. We...